Search Within

Efrat Luttwak

Formats
  1. Meeting Abstract (28)
  2. Journal Article (8)
  3. Research Letter (2)
  4. Editorial (1)
  5. Review (1)
Groups
  1. GME, Medicine (40)
  2. Graduate Medical Education (40)
  3. Center for Hematologic Malignancies (38)
  4. Department of Medicine (38)
  5. Hematologic Malignancies, Division of (38)
  6. Lymphoma (38)

More Groups

People
  1. Maria Palomba (34)
  2. Gilles Salles (32)
  3. Gunjan Shah (20)
  4. Alison Moskowitz (18)
  5. Ariela Noy (18)
  6. Lorenzo Falchi (18)

More People

Years
  1. 2025 (6)
  2. 2024 (20)
  3. 2023 (14)
Publications
  1. Blood (27)
  2. Blood Cancer Journal (2)
  3. Bone Marrow Transplantation (2)
  4. Leukemia and Lymphoma (2)
  5. Blood Advances (1)
  6. Blood Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (28)
  2. Nature Publishing Group (4)
  3. Taylor & Francis Group (2)
  4. American Association for Cancer Research (1)
  5. Biomed Central Ltd (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of immune reconstitution and their clinical significance in aggressive lymphoma treated with CAR-T therapy
    Meeting Abstract

    Luan, D. Y.; Dewolf, S.; Fei, T.; Raj, S. S.; Shah, G. L.; Lareau, C.; Alhomoud, M.; Salles, G.; Rivas-Delgado, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Functional geriatric assessment tests predict toxicity rates in functional high risk myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone in a prospective clinical trial
    Meeting Abstract

    Shmuel, R.; Tellem, R.; Gatt, M. E.; Lavi, N.; Ganzel, C.; Luttwak, E.; Chubar, E.; Rouvio, O.; Vaxman, I.; Pasvolsky, O.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save